ROLE OF LONG-TERM INTERMITTENT USE OF ORAL AZITHROMYCIN ON PULMONARY EXACERBATIONS IN CYSTIC FIBROSIS CHILDREN

Danish Abdul Aziz, Shahira Shahid, Haissan Iftikhar, Fatima Mir

Abstract


Background: Pulmonary exacerbation is the most common acute event occurring in a patient with cystic fibrosis and Pseudomonas aeruginosa is the most commonly involved organism. Azithromycin have antimicrobial and immunomodulatory effects on lungs and our study aimed to determine the role of long-term intermittent use of oral azithromycin on pulmonary exacerbations in children with cystic fibrosis. Methods: A retrospective cohort study was conducted from January 2012 to December 2016 at a tertiary care hospital, Aga Khan University Hospital, Karachi. The criteria for enrolment included cystic fibrosis patients aged 3–18 years who were classified into two groups based on their antibiotic use. The Azithromycin group included those CF patients who were on three days per week oral Azithromycin (10 mg per Kg per day) for 6 months. The non-azithromycin group included CF patients who were not on long term oral azithromycin. Our primary outcome was to assess the reduction in the number of exacerbations. Results: Sixty-three patients with a mean age (10.06±3.80) and mean pulmonary exacerbations of (3.67±1.58) in the 6 months before enrolment were included in our study. Out of these, 30 patients were included in the azithromycin group and 33 patients in the non-azithromycin group. Overall, 180 exacerbations were documented during the study period. The one-way ANOVA (F (1,61) =8.033, p<0.05) demonstrated a statistically significant difference in the mean number of exacerbations between the azithromycin (2.70±1.72) and non-azithromycin group (3.81±1.40) however, the mean length of stay between the groups was not significant (p=0.582). P. aeruginosa was found to be the most predominant colonizer of the airways. Conclusion: Long term low dose azithromycin therapy is beneficial in young patients with cystic fibrosis. It is an effective prevention strategy for pulmonary exacerbations.

Keywords: Cystic Fibrosis, pulmonary Exacerbation, Macrolide

Full Text:

PDF

References


Cogen JD, Oron AP, Gibson RL, Hoffman LR, Kronman MP, Ong T, et al. Characterization of Inpatient Cystic Fibrosis Pulmonary Exacerbations. Pediatrics 2017;139(2):e20162642.

Abdul Aziz D, Billoo AG, Qureshi A, Khalid M, Kirmani S. Clinical and laboratory profile of children with Cystic Fibrosis: Experience of a tertiary care center in Pakistan. Pak J Med Sci 2017;33(3):554–9.

Sanders DB, Fink AK. Background and Epidemiology. Pediatr Clin North Am 2016;63(4):567–84.

Shah U, Frossard P, Moatter T. Cystic fibrosis: defining a disease under-diagnosed in Pakistan. Trop Med Int Health 2009;14(5):542–5.

Goss CH, Burns JL. Exacerbations in cystic fibrosis 1: Epidemiology and pathogenesis. Thorax 2007;62(4):360–7.

Boucher RC. New concepts of the pathogenesis of cystic fibrosis lung disease. Eur Respir J 2004;23(1):146–58.

Bonfield TL, Panuska JR, Konstan MW, Hilliard KA, Hilliard JB, Ghnaim H, et al. Inflammatory cytokines in cystic fibrosis lungs. Am J Respir Crit Care Med 1995;152(6):2111–8.

Konstan MW, Hilliard KA, Norvell TM, Berger M. Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation. Am J Respir Crit Care Med 1994;150(2):448–54.

Rosenfeld M, Emerson J, Williams-Warren J, Pepe M, Smith A, Montgomery AB, et al. Defining a pulmonary exacerbation in cystic fibrosis. J Pediatr 2001;139(3):359–65.

Liou TG. Survival Effect of Lung Transplantation Among Patients With Cystic Fibrosis. JAMA 2001;286(21):2683–9.

Liou TG, Adler FR, Huang D. Use of Lung Transplantation Survival Models to Refine Patient Selection in Cystic Fibrosis. Am J Respir Crit Care Med 2005;171(9):1053–9.

Ferkol T, Rosenfeld M, Milla CE. Cystic fibrosis pulmonary exacerbations. J Pediatr 2006;148(2):259–64.

Saiman L, Marshall BC, Mayer-Hamblett N, Burns JL, Quittner AL, Cibene DA, et al. Azithromycin in Patients with Cystic Fibrosis Chronically Infected with Pseudomonas aeruginosa: A Randomized Controlled Trial. JAMA 2003;290(13):1749–56.

Flume PA, Mogayzel PJ, Robinson KA, Goss CH, Rosenblatt RL, Kuhn RJ, et al. Cystic Fibrosis Pulmonary Guidelines: Treatment of Pulmonary Exacerbations. Am J Respir Crit Care Med 2009;180(9):802–8.

Nichols DP, Odem-Davis K, Cogen JD, Goss CH, Ren CL, Skalland M, et al. Pulmonary Outcomes Associated with Long-Term Azithromycin Therapy in Cystic Fibrosis. Am J Respir Crit Care Med 2020;201(4):430–7.

Parnham MJ, Haber VE, Giamarellos-Bourboulis EJ, Perletti G, Verleden GM, Vos R. Azithromycin: Mechanisms of action and their relevance for clinical applications. Pharmacol Ther 2014;143(2):225–45.

Equi A, Balfour-Lynn I, Bush A, Rosenthal M. Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet 2002;360(9338):978–84.

Čulić O, Eraković V, Čepelak I, Barišić K, Brajša K, Ferenčić Ž, et al. Azithromycin modulates neutrophil function and circulating inflammatory mediators in healthy human subjects. Eur J Pharmacol 2002;450(3):277–89.

Mogayzel PJ, Naureckas ET, Robinson KA, Mueller G, Hadjiliadis D, Hoag JB, et al. Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2013;187(7):680–9.


Refbacks

  • There are currently no refbacks.


Contact Number: +92-992-382571

email: [jamc] [@] [ayubmed.edu.pk]